# reload+after+2024-01-23 11:43:44.344764
address1§An der Goldgrube 12
city§Mainz
zip§55131
country§Germany
phone§49 6131 9084 0
fax§49 6131 9084 390
website§https://www.biontech.de
industry§Biotechnology
sector§Healthcare
longBusinessSummary§BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
fullTimeEmployees§5700
companyOfficers§[{'maxAge': 1, 'name': 'Prof. Ugur  Sahin M.D.', 'age': 58, 'title': 'Co-Founder, CEO & Chair of the Management Board', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 488638, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ozlem  Tureci M.D.', 'age': 56, 'title': 'Co-Founder, Chief Medical Officer & Member of Management Board', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 908252, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jens H. Holstein', 'age': 60, 'title': 'CFO & Member of Management Board', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 956459, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sierk  Poetting Ph.D.', 'age': 50, 'title': 'MD, COO & Member of Management Board', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1004665, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Richardson', 'age': 44, 'title': 'Chief Strategy Officer, MD & Member of Management Board', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 485351, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sean  Marett', 'age': 58, 'title': 'Chief Business Officer, Chief Commercial Officer & Member of Management Board', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 931260, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James Timothy Patrick Ryan Ph.D.', 'age': 48, 'title': 'Chief Legal Officer & Member of the Management Board', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Sylke  Maas Ph.D.', 'title': 'Vice President of Investor Relations and Business Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Michael  Boehler', 'title': 'MD & Head of Global External Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Oliver  Hennig Ph.D.', 'title': 'Senior Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§8
shareHolderRightsRisk§1
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1654128000
payoutRatio§0.0
beta§0.271
priceToSalesTrailing12Months§4.0106025
currency§USD
dateShortInterest§1702598400
forwardEps§3.05
pegRatio§-0.34
exchange§NMS
quoteType§EQUITY
shortName§BioNTech SE
longName§BioNTech SE
firstTradeDateEpochUtc§1570714200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ec5204aa-33b4-3ae1-bc3a-4bb94e6f559d
gmtOffSetMilliseconds§-18000000
targetHighPrice§182.58
targetLowPrice§99.32
targetMeanPrice§129.89
targetMedianPrice§116.21
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§16
quickRatio§9.986
earningsGrowth§-0.904
grossMargins§0.90871
ebitdaMargins§0.62076
trailingPegRatio§None
